CClinicalTrials.gg
RecruitingNCT06072378Updated Dec 17, 2025

The Computational and Neural Mechanisms Linking Decision-making and Memory in Humans

An interventional study of Value-manipulation in Memory, Short-Term, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Learning to make good decisions in the present, and accurately recalling events and information from the past, are critical aspects of human cognition that are often impaired in many psychiatric disorders. This project aims to identify the how the choices individuals make influence what, and how, people remember by combining disparate techniques in computational modeling and direct brain recordings in human subjects. The researcher developed a dual-task paradigm, probing how decisions in one task affect immediate recognition memory. To examine the neural mechanisms underlying model-free RL's influence on memory, the researcher will record local field potential (LFP) and single neuron activity in various brain regions as epilepsy patients perform the proposed task. The results of this project will identify specific neurocomputational mechanisms unifying decision-making and memory processes.

02

Conditions studied

  • Memory, Short-Term
03

In context

Lead sponsor

Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Has seizure activity which is deemed non-responsive to standard pharmacological intervention(s), as determined by treating Neurologist and established clinical practices
  • Has elected to receive clinically indicated intracranial EEG (electrocorticography (ECoG), stereoelectroencephalography (SEEG)) and/or temporal responsive neurostimulation (RNS) for medication-refractory epilepsy outside of this research study, as determined by treating clinician(s) and per current clinical practice
  • Capacity to provide written informed consent
  • Language proficiency in English or Spanish
  • Willing and able to comply with all study-related procedures

Exclusion criteria

Exclusion Criteria:

  • History of psychosis, such as in the context of depressive or manic episode.
  • Active suicidal ideation with intent, suicide attempt within the last six months, or other serious suicide risk
  • Inability to provide informed consent or reliably participate in study assessments, as per the Montreal Cognitive Assessment (MOCA; score \< 26) or in the opinion of the evaluating neuropsychologist.
  • Individuals unwilling or unable to undergo electrode implantation procedures
  • Medical contraindications to neurosurgery or for general anesthesia, neurosurgery, or an MRI scan (required for electrode implantation)
  • Neurological disorder other than epilepsy or other significant brain pathology, if contraindicated in the opinion of implanting neurosurgeon.
  • Women who are pregnant
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Value-manipulation

    Participants with epilepsy will complete a behavioral task in which they use a laptop computer to do a decision-making and memory task.

    Behavioral: Value-manipulation

Interventions

  • BehavioralValue-manipulation

    During the decision-making task, different choices are assigned different values probabilistically.

06

What researchers measure

Primary outcomes

  1. Local-field potentials changes

    Detection of local-field potentials (LFPs) in the various regions (hippocampus, amygdala, and frontal cortex). Local field potentials are the biological voltages recorded by macroelectrodes implanted in participant's subcortical regions as part of their treatment for epilepsy. LFP changes (measured as increases or decreases in voltage) as a function of participant behavior will be recorded, and in response to the task manipulation of the value of choices during the decision-making task

    Time frame: During task participation, approx. 30-45 min in the first 2 weeks of hospital stay

  2. Firing rate changes

    Single-neuron activity recorded from the hippocampus, amygdala, and frontal cortex. Single-neuron activity refers the micro-scale changes in single-neuron action potentials recorded by microelectrodes implanted in subcortical regions. Firing rate changes (measured as difference in spikes/seconds \[Hz\]) will be reported for neurons as a function of how behavior changes when the value of choices is altered.

    Time frame: During task participation, approx. 30-45 min in the first 2 weeks of hospital stay

Secondary outcomes

  1. Reaction time

    Reaction times involve measuring how quickly the participant makes each choice during the decision-making and memory tasks, in milliseconds. This will be recorded by logging keypresses and mouse inputs to the behavioral computers. Slow reaction times indicate increased cognitive processing.

    Time frame: During task participation, approx. 30-45 min in the first 2 weeks of hospital stay

  2. Number of hit rates for decision-making

    Choices in decision-making task involved logging the decision-making selections that participants make. This will be recorded by logging keypresses and mouse inputs (left or right) to the behavioral computers. This will be used to track whether participants decisions change when value manipulations occur.

    Time frame: During task participation, approx. 30-45 min in the first 2 weeks of hospital stay

  3. Number of hit rates for Memory performance

    Memory performance involved logging the memory-recognition selections that participants make. This will be recorded by logging keypresses and mouse inputs (old or new) to the behavioral computers. This will be used to track whether participants memory performance changes when value manipulations occur.

    Time frame: During task participation, approx. 30-45 min in the first 2 weeks of hospital stay

07

Study locations

1 of 1 sites recruiting
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
    • Salman E Qasim · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to the raw, de-identified behavioral and neural data will be limited to qualified researchers due to the potential for misuse of participant demographic and neural data within 12 months following article publication. Datasets generated by this project will be made available through the National Institute of Mental Health Data Archive (NDA).

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06072378
Lead sponsor
Rutgers, The State University of New Jersey
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Salman Ehtesham Qasim, Ph.D. (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Oct 10, 2023
Start date
Oct 31, 2023
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Dec 17, 2025

Study contacts

Salman E Qasim, PhD
Contact
salman.qasim@mssm.edu
212-824-9531
Salman E Qasim, PhD
principal investigator · Icahn School of Medicine at Mt. Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion